This Pharmacy Times Peer Exchange episode discusses the growing clinical and economic burden of endometrial cancer, highlighting rising incidence, disparities in outcomes, and the need for improved screening, clinical trial enrollment, and evolving treatment strategies.
This episode examines the importance of overall survival as a key end point in endometrial cancer, comparing emerging data for pembrolizumab and dostarlimab and how these findings influence immunotherapy selection and clinical decision-making.
Overall survival (OS) guides first-line endometrial cancer choices, as RUBY trial data show mature dostarlimab benefit, while pembrolizumab OS is pending.
Clinicians compare PD-1 immunotherapies in endometrial cancer, weighing trial differences, progression-free survival, response rates, toxicity, and long-term quality of life.
The panelists examined the broadening treatment landscape beyond PD-1 inhibitors, highlighting the significant role of trastuzumab in human epidermal growth receptor 2 (HER2)–overexpressing uterine serous and carcinosarcoma subtypes.
Explore evolving endometrial cancer treatments: HER2-targeted trastuzumab, ADCs, and immunotherapy sequencing, plus NCCN guidance for dMMR and pMMR.
Pharmacists tackle formulary limits, shortages, and EHR lag to streamline endometrial cancer immunotherapy, including quick sub-Q dosing.
Immunotherapy strains budgets: copays, toxicity, and how pharmacists use NCCN evidence blocks to steer value-based cancer care.
Experts unpack immunotherapy copays, hidden costs, and side effects—plus how pharmacists use NCCN evidence blocks to guide choices.
Explore how clinical pathway lag shapes endometrial cancer care—and how pharmacists drive updates, collaboration, and smarter therapy sequencing.
Pharmacists boost biomarker testing access and education, streamline therapy approvals, and guide safe immunotherapy dosing in endometrial cancer through proactive IRAE monitoring.
Discover how pharmacists drive biomarker testing, speed therapy approvals, and guide safer immunotherapy decisions in endometrial
